4-[[(4-Fluorophenyl)imino]methyl]-phenol CAS 3382-63-6 Ezetimibe Purità Intermedja ≥99.0% Fabbrika
Provvista tal-Manifattur;Kwalità Għolja u Prezz Kompetittiv
Provvista Kummerċjali Ezetimibe (CAS: 163222-33-1) Intermedji Relatati:
(S)-(+)-4-Phenyl-2-oxazolidinone CAS: 99395-88-7
(R)-(+)-2-Methyl-CBS-oxazaborolidine CAS: 112022-83-0
4-(4-Fluorobenzoyl)butyric acid CAS: 149437-76-3
4-[[(4-Fluorophenyl)imino]methyl]-phenol CAS: 3382-63-6
N-(4-(Benzyloxy)benzylidene)-4-fluoroaniline CAS: 70627-52-0
(3R,4S)-4-[4-(Benzyloxy)phenyl]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one CAS: 190595-65 -4
(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone CAS: 189028-93-1
(4S)-3-[(5S)-5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one CAS: 189028-95-3
Ezetimibe CAS: 163222-33-1
Isem Kimiku | 4-[[(4-Fluorophenyl)imino]methyl]-phenol |
Numru CAS | 3382-63-6 |
Numru CAT | RF-PI145 |
Status tal-istokk | Fil-Ħażna, Skala ta' Produzzjoni Sa Tunnellati |
Formula Molekulari | C13H10FNO |
Piż Molekulari | 215.22 |
Punt tat-tidwib | 179.0 sa 183.0℃ |
Brand | Ruifu Kimika |
Oġġett | Speċifikazzjonijiet |
Dehra | Off-White għal Trab Abjad |
Purità / Metodu ta 'Analiżi | ≥99.0% (HPLC) |
Telf fuq Tnixxif | ≤0.50% |
Impurità Unika | ≤0.50% |
Impuritajiet Totali | ≤1.0% |
Metalli Tqil | ≤20ppm |
Standard tat-Test | Standard tal-Intrapriża |
Użu | Ezetimibe (CAS: 163222-33-1) Intermedju |
Pakkett: Flixkun, borża tal-fojl tal-aluminju, tanbur tal-kartun, 25kg/Drum, jew skont il-ħtieġa tal-klijent.
Kundizzjoni tal-Ħżin:Aħżen f'kontenituri ssiġillati f'post frisk u niexef;Ipproteġi mid-dawl, l-umdità u l-infestazzjoni tal-pesti.
![1](https://www.ruifuchemical.com/uploads/15.jpg)
![2](https://www.ruifuchemical.com/uploads/23.jpg)
Shanghai Ruifu Chemical Co., Ltd hija l-manifattur u l-fornitur ewlieni ta '4-[[(4-Fluorophenyl)imino]methyl]-phenol (CAS: 3382-63-6) bi kwalità għolja, huwa intermedju ta' Ezetimibe ( CAS: 163222-33-1).Ezetimibe huwa mediċina kontra l-iperlipidemija użata biex tnaqqas il-livelli tal-kolesterol fil-plażma.Ezetimibe huwa inibitur tat-trasport tal-kolesterol li jeħel ma' NPC1L1.Huwa indikat bħala terapija aġġuntiva għad-dieta għat-tnaqqis ta 'livell għoli ta' C totali, LDL-C, u ApoB f'pazjenti li jsofru iperkolesterolemija primarja (familjari eterozigota u mhux familjari).